UC Irvine

ABSTRACT

Loss of function mutations at the retinoblastoma ( RB1 ) gene are associated with increased mortality, metastasis and poor therapeutic outcome in several cancers, including osteosarcoma (OS). However, the mechanism(s) through which RB1 loss worsens clinical outcome remain to be elucidated. Ubiquitin-like with PHD and Ring Finger domains 1 (UHRF1) has been identified as a critical downstream effector of the RB/E2F signaling pathway that is overexpressed in various cancers. Here, we show that UHRF1 upregulation is critical in rendering OS cells more aggressive. Using novel OS genetically engineered mouse models, we determined that knocking-out Uhrf1 considerably reverses the poorer survival associated with Rb1 loss. We also found that high UHRF1 expression correlates with increased clinical presentation of metastatic disease. Based on gain- and loss-of-function assays, we found that UHRF1 promotes cell proliferation, migration, invasion, and metastasis. UHRF1-mediated cell mobility results as a consequence of altered extracellular vesicles and their cargo, including urokinase-type plasminogen activator (uPA). Our work presents a new mechanistic insight into RB1 loss-associated poor prognosis and a novel oncogenic role of UHRF1 through regulation of exosome secretion that is critical for OS metastasis. This study provides substantial support for targeting UHRF1 or its downstream effectors as novel therapeutic options to improve current treatment for OS.